Physician profile
Samuel L Ahn
NPI 1720163694
$8,995.36
in general payments reported to CMS, 2019-2025
12 companies · $773 in 2025
The $773 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $225 · 2021: $408 · 2022: $918 · 2023: $2,441 · 2024: $3,262 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,348 · Travel and Lodging: $3,120 · Education: $7.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,348.14 |
| Travel and Lodging | $3,120.24 |
| Education | $7.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $3,524.94 | 2019-2025 | Cvi Contact Lens, Misight Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $3,233.97 | 2019-2025 | Acuvue |
| Lumenis Be INC | $704.95 | 2024 | Optilight |
| Alcon Vision LLC | $511.69 | 2019-2025 | Argos, Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $459.16 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $121.78 | 2023 | Cequa |
| Abb Con-Cise Optical Group LLC | $117.78 | 2019 | |
| Bausch & Lomb Americas INC. | $98.42 | 2022-2025 | Infuse |
| Optos, INC. | $95.11 | 2019-2021 | |
| Topcon Healthcare, INC. | $90.43 | 2019 | |
| Oyster Point Pharma, INC. | $19.89 | 2025 | Tyrvaya, Ryzumvi |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Ahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.